PTAB Upholds Bausch Patent Following Federal Circuit Remand
By Editorial Team
The Patent Trial and Appeal Board (PTAB) has reaffirmed its decision that MSN Laboratories did not demonstrate the invalidity of a drug patent held by Bausch Health Ireland Ltd. This ruling comes after the Federal Circuit instructed the board to revisit the matter last year.
Bausch Health Ireland Ltd. owns a patent (7,041,786) related to guanylate cyclase receptor agonists for treating tissue inflammation and carcinogenesis. The PTAB’s recent decision upholding the validity of this patent marks a significant development in the ongoing legal battle between the two pharmaceutical companies.
Law360 reported that the law firms involved in the case include ArentFox Schiff and Finnegan, representing Bausch Health Cos. Inc., Salix Pharmaceuticals, Ltd., and Viatris Inc. On the government side, the Food and Drug Administration and the Patent Trial and Appeal Board were also involved in the matter.
With the PTAB’s decision to uphold the Bausch patent, the pharmaceutical landscape may see further implications and potential shifts in the competitive dynamics within the industry. This ruling underscores the importance of patent protection and the complexities involved in patent disputes within the pharmaceutical sector.
For more detailed information on the case, interested parties can access the attached documents related to the PTAB’s decision. The case has been closely followed by legal experts and industry stakeholders due to its potential impact on intellectual property rights and drug development within the life sciences sector.
